Ypsomed expands headquarters in Burgdorf

Press Releases Ypsomed Group

Burgdorf – Ypsomed opens its new and renovated buildings at the headquarters in Burgdorf. With this expansion, Ypsomed secures the additional capacities and workplaces it needs to continue growing in the future.

Ypsomed opens production plant in Schwerin, Germany

Press Releases Ypsomed Group

Burgdorf – Ypsomed opens its new production plant in Schwerin, in north-eastern Germany. Ypsomed is thus ensuring the necessary production capacities for growth in the coming years. Around 200 jobs will be created at the new production site over the next few years.

Ypsomed expands to North America

Press Releases Ypsomed Group

Burgdorf – In the financial year 2018/19, Ypsomed achieved consolidated sales of CHF 453.8 million (previous year: CHF 466.1 million). In continuing operations, Ypsomed achieved a sales growth of CHF 68.4 million, which represents an increase of 24%. The operating result (EBIT) amounts to CHF 73.3 million (previous year: CHF 61.1 million). Net profit for the 2018/19 financial year amounts to CHF 60.1 million (previous year: CHF 52.1 million).

Copaxone PEN from Teva
Copaxone PEN

Press Releases Ypsomed Group

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector YpsoMate® from Ypsomed. Copaxone® is used for the treatment of patients with relapsing forms of multiple sclerosis (MS). The collaboration with Teva marks the second commercial market entry of Ypsomed’s autoinjector YpsoMate®.

Ypsomed Headquarters in Burgdorf (Switzerland)

Press Releases Ypsomed Group

Burgdorf – No agreement has been reached between Ypsomed and Insulet Corp., its former supplier of Omnipod® devices on the amount of the expiration fee payable to Ypsomed under the terms of the distribution agreement that expired in June 2018. After unsuccessful attempts to amicably agree on the amount, Ypsomed has decided to file for arbitration. Ypsomed continues to estimate the expiration fee to amount to approximately CHF 50 million.